| Isatuximab studied in …STUDIED_INderived68 of 68show fewer |
|---|
| → studied in | NCT07652905Phase 2 · recruiting CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia · 68 trials list this drug (50 active) | — | — | Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883242Phase 2 · active not recruiting Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06832865Phase 2 · recruiting ELISA in Relapsed/Refractory MM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06182774Phase 3 · recruiting Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06517017Phase 2 · recruiting Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624513Phase 3 · not yet recruiting D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07601100Phase 1/Phase 2 · not yet recruiting Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05405166Phase 3 · active not recruiting SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM · 68 trials list this drug (50 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272826Phase 2 · recruiting Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07479979Phase 1/Phase 2 · recruiting Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05344833Phase 2 · recruiting Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06648889Phase 2 · recruiting Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia · 68 trials list this drug (50 active) | — | — | T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06216158Phase 3 · active not recruiting Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764978Phase 3 · recruiting Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05669989Phase 2 · enrolling by invitation International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07732712Phase 2/Phase 3 · not yet recruiting Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05346809Phase 2 · active not recruiting Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma · 68 trials list this drug (50 active) | — | — | Lymphoma,Multiple Myeloma,Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05690984Phase 2 · active not recruiting Elimination of Minimal Residual Disease After Transplant · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04754945Phase 1 · active not recruiting Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis · 68 trials list this drug (50 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04850599Phase 2 · active not recruiting Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203912Phase 1 · completed Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05558319Phase 3 · recruiting NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07217184Phase 1/Phase 2 · active not recruiting Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07663253recruiting Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04643002Phase 1/Phase 2 · recruiting Isatuximab in Combination With Novel Agents in RRMM - Master Protocol · 68 trials list this drug (50 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332850Phase 1 · completed Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05911321Phase 2 · active not recruiting Isa-Pom-Dex in Elderly/Frail Subjects With RRMM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05776979Phase 2 · recruiting Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430894Phase 2 · active not recruiting KRDI in Transplant-Eligible MM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05145400Phase 2 · recruiting Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07600151Phase 1/Phase 2 · not yet recruiting Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03104842Phase 2 · active not recruiting Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126200Phase 1/Phase 2 · active not recruiting Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04653246Phase 2 · active not recruiting Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04763616Phase 2 · completed Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy · 68 trials list this drug (50 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02960555Phase 2 · active not recruiting Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) · 68 trials list this drug (50 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05873205Phase 2 · active not recruiting Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation · 68 trials list this drug (50 active) | — | — | Liquid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835129Phase 2 · active not recruiting Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05804032Phase 3 · completed Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04751877Phase 3 · active not recruiting Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03617731Phase 3 · active not recruiting Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04240054Phase 2 · recruiting Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922501Phase 2 · recruiting Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Malignant Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05704049Phase 2 · active not recruiting A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03499808Phase 2 · completed S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis · 68 trials list this drug (50 active) | — | — | Primary Amyloidosis,Primary Systemic Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03860844Phase 2 · terminated Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia · 68 trials list this drug (50 active) | — | — | Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06762769Phase 2 · recruiting Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma · 68 trials list this drug (50 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07045909Phase 2 · recruiting Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · 68 trials list this drug (50 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05123131Phase 2 · active not recruiting Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119685Phase 1/Phase 2 · recruiting IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · 68 trials list this drug (50 active) | — | — | Liquid Tumor,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04891809Phase 2 · active not recruiting Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02990338Phase 3 · completed Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05665140Phase 2/Phase 3 · recruiting Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989414Phase 1/Phase 2 · active not recruiting A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04934475Phase 3 · active not recruiting MInimal Residual Disease Adapted Strategy · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03530683Phase 1 · terminated A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Lymphoma,Multiple Myeloma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05284032early Phase 1 · terminated A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) · 68 trials list this drug (50 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083898Phase 1 · terminated Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05066607Phase 2 · unknown Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy · 68 trials list this drug (50 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04912427Phase 1 · terminated Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03555149Phase 1/Phase 2 · terminated A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) · 68 trials list this drug (50 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04558931Phase 2 · recruiting Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04287855Phase 2 · unknown Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514668Phase 1 · completed A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma · 68 trials list this drug (50 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05147493Phase 2 · unknown A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment · 68 trials list this drug (50 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05298683Phase 2 · unknown A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor · 68 trials list this drug (50 active) | — | — | Neoplasm,Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114109Phase 2 · unknown Isatuximab in Type I Cryoglobulinemia · 68 trials list this drug (50 active) | — | — | Multiple Myeloma,Monoclonal Gammopathy of Undetermined Significance | 1 | Observed | clinicaltrials | graph → |